Myeloma cells also increase the activity of osteoclasts (cells that damage bone). In a study of over 200 people with multiple myeloma, 37% of subjects reported bone pain as their first symptom ...

Researchers at Uppsala University have identified a promising therapeutic approach for the challenging blood cancer multiple myeloma.

Multiple myeloma is predominantly a disease of the elderly, with the median age at diagnosis about 70; one-third of patients are older than 75, and 10% are older than 80.

Discover the current challenges in diagnosing multiple myeloma and how advances in diagnostic technologies could help patients suffering.

The FDA’s approval of linvoseltamab for adults with heavily pretreated relapsed/refractory multiple myeloma marks a significant advance, with Sundar Jagannath, MBBS, emphasizing its high ...

A bid by GlaxoSmithKline (GSK) to bring its multiple myeloma drug belantamab mafodotin (Blenrep) back to the market hit a stumbling block during an FDA panel meeting held on July 17.

For Your Patients: Getting to Know the Options for Newly Diagnosed Multiple Myeloma — New drug regimens, with or without transplant, are improving quality of life, prolonging survival ...

Genetic and epigenetic mechanisms drive GPRC5D loss after CAR T-cell therapy in multiple myeloma.

89 percent of 509 patients would have been ineligible for MajesTEC-1 trial; estimated median PFS was 5.8 months.

PURPOSETo better understand the priorities that guide patients with multiple myeloma, we surveyed patients on four different treatment scenarios, each of treatment strategies shown to improve ...

The combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including Switzerland and Canada.

On a quest to bring its multiple myeloma antibody-drug conjugate Blenrep back to the U.S. | Members of the FDA's Oncologic Drugs Advisory Committee voiced concerns with ocular toxicity side ...